Literature DB >> 16978753

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals.

Bankole A Johnson1, John D Roache, Nassima Ait-Daoud, Lynda T Wells, Christopher L Wallace, Michael A Dawes, Lei Liu, Xin-Qun Wang.   

Abstract

Methamphetamine-dependent individuals often cite the need to maintain enhanced cognitive performance and attention as a reason for continuing or relapsing to drug-taking. Further, methamphetamine addicts might not comply with taking a potentially therapeutic medication if it had a profound effect on these cognitive processes. Topiramate, a sulfamate-substituted fructopyranose derivative, has been suggested as a putative therapeutic medication for treating methamphetamine dependence. Examination of topiramate's effects on cognitive performance and attention is a clinically and scientifically important component of understanding its potential therapeutic profile. In 10 male and female individuals who met DSM-IV criteria for methamphetamine dependence, we examined the effects of low (50 mg b.i.d.)- and high (100 mg b.i.d.)-dose topiramate - in both the presence and absence of low (15 mg)- and high (30 mg)-dose intravenous methamphetamine--on cognitive performance, attention, and concentration on the rapid visual information processing task and the digit symbol substitution test. Intravenous methamphetamine enhanced cognitive performance, attention, and concentration among recently withdrawn methamphetamine addicts--an effect that hitherto had not been well characterized. Topiramate's cognitive effects were mixed and rather paradoxical, with a tendency to improve attention and concentration both alone and in the presence of methamphetamine while worsening psychomotor retardation. No deleterious interaction occurred between topiramate and methamphetamine on any of these cognitive processes. While clinical studies with topiramate should prepare participants for possible psychomotor retardation, the cognitive effects profile observed would not likely present an important obstacle to compliance in motivated patients. Topiramate's complicated cognitive effects among methamphetamine addicts need more comprehensive examination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978753      PMCID: PMC1810424          DOI: 10.1016/j.pnpbp.2006.08.002

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  35 in total

1.  Use ecology and drug use motivations of methamphetamine users admitted to substance abuse treatment facilities in Los Angeles: an emerging profile.

Authors:  Mayrhauser Christina von; Mary-Lynn Brecht; M Douglas Anglin
Journal:  J Addict Dis       Date:  2002

2.  Status epilepticus-induced neuronal loss in humans without systemic complications or epilepsy.

Authors:  D G Fujikawa; H H Itabashi; A Wu; S S Shinmei
Journal:  Epilepsia       Date:  2000-08       Impact factor: 5.864

3.  Effects of acute topiramate dosing on methamphetamine-induced subjective mood.

Authors:  Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Lynda T Wells; Christopher L Wallace; Michael A Dawes; Lei Liu; Xin-Qun Wang
Journal:  Int J Neuropsychopharmacol       Date:  2006-02-01       Impact factor: 5.176

4.  Postmarketing experience with topiramate and cognition.

Authors:  W O Tatum; J A French; E Faught; G L Morris; J Liporace; A Kanner; S L Goff; L Winters; A Fix
Journal:  Epilepsia       Date:  2001-09       Impact factor: 5.864

5.  Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication.

Authors:  Edgar Kockelmann; Christian E Elger; Christoph Helmstaedter
Journal:  Epilepsy Behav       Date:  2004-10       Impact factor: 2.937

6.  Effects of isradipine on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition.

Authors:  Bankole A Johnson; John D Roache; Nassima Ait-Daoud; Christopher Wallace; Lynda T Wells; Yanmei Wang
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

7.  Oral topiramate for treatment of alcohol dependence: a randomised controlled trial.

Authors:  Bankole A Johnson; Nassima Ait-Daoud; Charles L Bowden; Carlo C DiClemente; John D Roache; Kevin Lawson; Martin A Javors; Jennie Z Ma
Journal:  Lancet       Date:  2003-05-17       Impact factor: 79.321

Review 8.  Modulation of brain dopamine transmission by sex steroids.

Authors:  T Di Paolo
Journal:  Rev Neurosci       Date:  1994 Jan-Mar       Impact factor: 4.353

9.  Memory and cognitive function in man: does the cholinergic system have a specific role?

Authors:  D A Drachman
Journal:  Neurology       Date:  1977-08       Impact factor: 9.910

10.  Forebrain norepinephrine: role in controlled information processing in the rat.

Authors:  B J Cole; T W Robbins
Journal:  Neuropsychopharmacology       Date:  1992-09       Impact factor: 7.853

View more
  14 in total

1.  Topiramate impairs cognitive function in methadone-maintained individuals with concurrent cocaine dependence.

Authors:  Olga Rass; Annie Umbricht; George E Bigelow; Eric C Strain; Matthew W Johnson; Miriam Z Mintzer
Journal:  Psychol Addict Behav       Date:  2014-11-03

2.  Repeated co-administrations of alcohol- and methamphetamine-produced anxiogenic effect could be associated with the neurotoxicity in the dentate gyrus.

Authors:  Jia-Ying Chuang; Wan-Ting Chang; Chianfang G Cherng; Gour-Shenq Kao; Lung Yu
Journal:  J Neural Transm (Vienna)       Date:  2011-04-17       Impact factor: 3.575

Review 3.  Topiramate in the treatment of substance-related disorders: a critical review of the literature.

Authors:  Ann K Shinn; Shelly F Greenfield
Journal:  J Clin Psychiatry       Date:  2010-03-09       Impact factor: 4.384

4.  Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals.

Authors:  Bankole A Johnson; Lynda T Wells; John D Roache; Christopher L Wallace; Nassima Ait-Daoud; Michael A Dawes; Lei Liu; Xin-Qun Wang; Martin A Javors
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-12-19       Impact factor: 5.067

Review 5.  Pharmacological approaches to methamphetamine dependence: a focused review.

Authors:  Laurent Karila; Aviv Weinstein; Henri-Jean Aubin; Amine Benyamina; Michel Reynaud; Steven L Batki
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

Review 6.  Is cognitive functioning impaired in methamphetamine users? A critical review.

Authors:  Carl L Hart; Caroline B Marvin; Rae Silver; Edward E Smith
Journal:  Neuropsychopharmacology       Date:  2011-11-16       Impact factor: 7.853

Review 7.  Pharmacotherapy of methamphetamine addiction: an update.

Authors:  Ahmed Elkashef; Frank Vocci; Glen Hanson; Jason White; Wendy Wickes; Jari Tiihonen
Journal:  Subst Abus       Date:  2008       Impact factor: 3.716

Review 8.  Biological treatments for amfetamine dependence : recent progress.

Authors:  Kevin P Hill; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 9.  Pharmacotherapy for stimulant-related disorders.

Authors:  Colin N Haile; Thomas R Kosten
Journal:  Curr Psychiatry Rep       Date:  2013-11       Impact factor: 5.285

Review 10.  Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.

Authors:  Jennifer M Loftis; Marilyn Huckans
Journal:  Pharmacol Ther       Date:  2013-04-28       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.